

JAN 24 2000

**510(k) Summary**

**Baby Dopplex® 4000**

Submitter's Name: Ms Audrey A. Witco,  
Director of Corporate Affairs,  
Huntleigh Healthcare,  
227 Route 33 East,  
Manalapan, NJ 07726  
USA

Telephone N°: (800) 223 1218 ext 127  
Fax N°: (732) 446 1938

**Name of Device: Baby Dopplex® 4000 (BD4000)**

**Manufactured by:** Huntleigh Diagnostics Ltd  
35, Portmanmoor Road,  
Cardiff  
South Glamorgan CF24 5HN  
Wales, U.K.

**Contact Person at Manufacturing Facility:**

B.J. Colleypriest  
Telephone N°: +44 (0) 1222 485885  
Fax N°: +44 (0) 1222 490170  
e-mail: bryn.colleypriest@huntleigh-diagnostics.co.uk

**Date summary prepared: 01 December 1999**

**Classification Name**

Fetal Ultrasonic Monitor and Accessories (21 CFR § 884.2660)

**Predicate Devices**

Baby Dopplex 3000 (ABD3000) K963711.  
Hewlett Packard GmbH's Series 50 range of Fetal Monitors Model N°s M1351A  
& M1353A (K921957 & K921956 respectively).

### Device Description

The BD4000 is a fetal monitor, which produces cardiotocographs (CTG) and gives indication of uterine activity by processing received ultrasound/electrical signals. In basic format, the device performs antepartum fetal monitoring and uterine activity functions. Connecting separate modules to the BD4000 main unit allows it to perform Intrapartum monitoring operations.

In instances of twin presentations, two Baby Dopplex® 4000 units can be linked together so that both fetuses can be monitored simultaneously.

The complete BD4000 system has been tested to ensure compliance with internationally recognised medical electrical equipment standards. Tests have been performed in accordance with the requirements of IEC601-1, BS EN60601-1, UL2601-1, BS EN 60601-1-2, BS EN55011 & DIN VDE 0750-1. A checklist of Essential Requirements tests has been compiled in accordance with the direction of the Medical Devices Directive 93/42/EEC. Biocompatibility has been assessed in line with the principles contained within BS EN30993-1 & ISO10993-1.

### Intended use

The BD4000 device performs the same functions as the Hewlett Packard predicate devices. The BD4000 can also monitor twins by linking two unmodified devices together.

The BD4000 is also an upgrade of the predicate ABD3000 (K963711), and includes intrapartum and twins monitoring functions that were not available on the previous model.

The fetal parameters are displayed in the same way as those of the predicate devices.

The following table briefly compares the monitoring characteristics of the applicant device to its predicate devices.

Monitoring Mode	Baby Dopplex® 4000	Baby Dopplex® 3000 (K963711)	Hewlett Packard M1351A (K921957)	Hewlett Packard M1353A (K921956)
Monitoring fetal heart rate using ultrasound	Yes	Yes	Yes	Yes
Monitoring twin fetal heart rate using ultrasound	Yes <sup>(1)</sup>	No	Yes <sup>(1)</sup>	No
Monitor fetal heart rate using FECCG	Yes <sup>(1)</sup>	No	Yes	Yes

NB: <sup>(1)</sup> optional feature.



JAN 24 2000

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850Ms. Audrey A. Witco  
Director of Corporate Affairs  
Huntleigh Healthcare  
227 Route 33 East  
Manalapan, NJ 07726Re: K990569  
Baby Dopplex® 4000  
Dated: December 1, 1999  
Received: December 9, 1999  
Regulatory Class: II  
21 CFR §884.2740/Procode: 85 HGM

Dear Ms. Witco:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

CAPT Daniel G. Schultz, M.D.  
Acting Director, Division of Reproductive,  
Abdominal, Ear, Nose and Throat,  
and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

